The American Academy of Dermatology (AAD) provided a strong, evidence-based recommendation for the use of VTAMA cream, the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence that is indicated across all severities in children aged 2 years and older with atopic dermatitis (AD)
This recommendation reflects the proven efficacy, safety, and tolerability of VTAMA cream as a first-in-class, steroid-free, topical aryl hydrocarbon receptor (AhR) agonist for children and adolescents with AD
AD, the most common form of eczema, impacts nearly 10 million children in the US
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that VTAMA creamwas granted a strong, evidence-based recommendation by the American Academy of Dermatology (AAD) in their 2026 guidelines for the management and treatment of atopic dermatitis (AD) in pediatric patients, published on April 7, 2026. The guidelines name VTAMA cream as the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence, that is indicated across all severities in children aged 2 years and older with AD. In the pivotal studies for VTAMA in AD, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

The 2026 AAD pediatric atopic dermatitis guidelines are the first pediatric-specific AD guidelines issued by the AAD, and underscore important considerations for pediatric versus adult dermatological care. The pediatric guidelines provide evidence-based recommendations for topical therapies (prescription and non-prescription), phototherapy, and systemic therapies, ensuring the dermatology community has access to the best available data when developing prevention and treatments plans for pediatric patients.